Accueil   Diary - News   All news Elsalys Biotech acquires a first-in-class antibody with a dual biological mechanism of action

Elsalys Biotech acquires a first-in-class antibody with a dual biological mechanism of action

Elsalys logo_vertical_CMJN

ELSALYS BIOTECH, a biopharmaceutical company that designs and develops "first-in-class" therapeutic antibodies against cancer and inflammatory diseases, today announced the acquisition of the development and marketing rights of the anti-CD160 antibody from the company MABLIFE.

 

 As the anti-CD160 antibody has shown its efficacy in cancer and eye disease animal models, ELSALYS BIOTECH has already initiated the preclinical evaluation of different humanised versions of this antibody in age-related macular degeneration, an eye disease associated with uncontrolled vascular proliferation.

 

 

The result of this study, which should lead to the selection of a first drug candidate, is expected in the first half of 2016.

 

 

Read the press release